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Abstract
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in
patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the
identification of resistance mutations mapping to the NS5B polymerase region. TGV does not inhibit NS5B enzymatic
activity in biochemical assays in vitro, suggesting a more complex antiviral mechanism with cellular components. Here, we
demonstrate that TGV exerts anti-HCV activity utilizing a unique chemical activation and subsequent direct interaction with
the NS5B protein. Treatment of HCV subgenomic replicon cells with TGV results in a modified form of NS5B with a distinctly
altered mobility on a SDS-PAGE gel. Further analysis reveals that the aberrantly migrating NS5B species contains the
inhibitor molecule. Formation of this complex does not require the presence of any other HCV proteins. The intensity of the
aberrantly migrating NS5B species is strongly dependent on cellular glutathione levels as well as CYP 1A activity.
Furthermore analysis of NS5B protein purified from a heterologous expression system treated with TGV by mass
spectrometry suggests that TGV undergoes a CYP- mediated intracellular activation step and the resulting metabolite, after
forming a glutathione conjugate, directly and specifically interacts with NS5B. Taken together, these data demonstrate that
upon metabolic activation TGV is a specific, covalent inhibitor of the HCV NS5B polymerase and is mechanistically distinct
from other classes of the non-nucleoside inhibitors (NNI) of the viral polymerase.
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Introduction
Hepatitis C Virus (HCV) is a major cause of morbidity and
mortality with an estimated 170 million people infected worldwide
and 3–4 million new infections acquired annually [1]. HCV, a
member of the Flaviviridae family, is a positive-strand RNA virus
with seven major genotypes each divided into a series of subtypes.
Additionally, each subtype exists as a quasispecies population
within an infected individual [2]. Current treatment utilizing the
combination of pegylated interferon (PEG) and ribavirin (RBV) is
fraught with significant side-effects and is of limited efficacy against
genotype 1 HCV, the most prevalent in the United States and
Europe [3,4]. The recent approvals of HCV NS3 protease
inhibitors telaprevir and boceprevir for use in combination with
PEG/RBV have significantly improved the effectiveness of the
therapy [5,6]. However, the significant side effects associated with
a PEG/RBV-based regimen still remain, and the new antiviral
agents have introduced additional tolerability issues. Furthermore,
these new treatment options have limited efficacy in certain
treatment populations (e.g. PEG-experienced or IL28B CT/TT
patients) [5,7,8]. Recent clinical studies utilizing direct acting
antivirals (DAA) in combination suggest that combinations of
multiple antivirals with different mechanisms of action and non-
overlapping resistance profiles may potentially cure a greater
number of HCV patients with shortened treatment duration and
even in the absence of PEG and/or RBV [9,10]. One such agent
currently being studied in antiviral combination trials is the non-
nucleoside inhibitor (NNI) tegobuvir (TGV).
Tegobuvir (TGV, GS-9190) is an analog of a novel class of
imidazopyridine inhibitors selectively targeting HCV [2]. TGV
demonstrated anti-HCV potency both in vitro and in vivo.I na
recent exploratory study using TGV in combination with the NS3
protease inhibitor GS-9256 and PEG/RBV, 100% of patients had
HCV RNA levels below the lower limit of quantification after only
28 days of treatment [10]. Despite its efficacy and safety in HCV-
infected patients, the molecular mechanism of action of TGV has
not been well understood. TGV selects (both in vitro and in
patients) for mutations in the NS5B polymerase at positions 316,
445, 448, and 452 that are responsible for a resistant phenotype
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strate that TGV potency in vitro is linked to NS5B genotype, again
indicating that TGV involves the polymerase as a target [2].
However, TGV is not active in biochemical polymerase assays
using recombinant NS5B proteins nor could we demonstrate TGV
NS5B interactions using various biophysical methods ([2] and
unpublished results).
However, these findings can be explained with the novel results
presented herein and when considering our recent evidence for the
involvement of metabolic activation. Briefly, when co-dosing
replicon-harboring cells with different cytochrome P450 inhibitors
[2], loss of sensitivity to TGV is observed. This suggests that TGV
employs a more complex mechanism of action to target HCV.
Here we show that TGV binds directly to the NS5B polymerase
after undergoing a unique, multistep metabolic activation pathway
that involves specific glutathione adducts.
Methods
Replicon cell lines
Huh7-Lunet cells were obtained from ReBlikon GmbH (Mainz,
Germany). Creation of Huh7-Lunet cells harboring a stable
genotype 1b (Con-1) or 1a (1a H77) replicon encoding a Renilla
luciferase reporter has been reported previously [13,14]. All
Huh7-Lunet containing replicon cell lines were grown in
Dulbeccos’s modified Eagle’s medium (DMEM) with Gluta-
MAX-I (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS; HyClone, Logan, UT), 1 U/ml penicillin
(Invitrogen), 1 ug/ml streptomycin (Invitrogen) and 0.1 mM
nonessential amino acids (Invitrogen). Stable replicon cell lines
were maintained in media containing 0.5 mg/ml G418 (Genet-
icin; Invitrogen). The stable HeLa replicon cell line (clone SL3)
was described previously and was obtained from the laboratory of
Dr. Christophe Seeger at Fox Chase Cancer Center (Philadelphia,
PA) [15]. HeLa replicon cells were grown in DMEM with 10%
fetal bovine serum in the presence of 0.5 mg/ml G418.
Compounds
TGV (GS-9190), VX-222, and compounds 1, 2, and 3 were
synthesized at Gilead Sciences, Inc. (Foster City, CA). BILN-2061
and 29-C-methyl adenosine (29CMeA) were purchased from Acme
Bioscience (Belmont, CA). NS5B site IV inhibitor HCV-796 was
synthesized by Curragh Chemistries (Cleveland, OH). The
benzothiadiazine NS5B polymerase inhibitor (A-782759) was
synthesized by ChemALong Laboratories (Lemont, IL).
Construction of a replicon carrying the Y448H NS5B
mutation
A Y448H NS5B point mutation was engineered using the
Stratagene Quikchange XL mutagenesis kit (Stratagene) and
appropriate primers into the pFK I341 PI-Luc/NS3-39/ET
replicon construct (ReBlikon GmbH) in which the firefly luciferase
reporter had been replaced with a Renilla luciferase reporter.
Presence of the mutation was confirmed by sequencing (Elim
Biopharmaceuticals, Inc., Hayward, CA), after which the NS5B
region was then subcloned into a fresh vector backbone using BclI
and SpeI restriction sites followed by further sequencing to
confirm sequence fidelity. For transfection, DNA plasmids
encoding replicon sequences were linearized in vitro using SpeI
restriction endonuclease (NEB) followed by electrophoresis and gel
purification of the linearized fragment (QIAquick gel extraction
kit; Qiagen). Replicon RNA was transcribed from the purified
template using T7 run-off transcription (MEGAscript T7 kit;
Ambion). For transfection of RNA into Huh-7 Lunet cells, cells
were trypsinized and washed three times with PBS. A suspension
of 4610
6 cells in 400 mL PBS was mixed with 10 mg RNA and
subjected to electroporation at settings of 270 V and 950 uF
capacitance. Cells were then transferred into 20 mL of pre-
warmed culture medium and seeded into appropriate plates for
further analyses.
Replicon EC50 determinations
Replicon-containing cells were trypsinized and seeded in cell
culture media without G418 in white 96-well plates for EC50
analysis. Stable replicon carrying cell lines were seeded at a density
of 5,000 cells per well. Serial threefold dilutions (10 concentrations)
of compounds were performed in DMSO followed by further
dilution in cell culture media and subsequent addition to cell
plates. Compound-treated cells were incubated 72 hours at 37uC
in a 5% CO2 incubator. For luciferase-encoding replicons, the
luciferase signal (in treated and untreated cells) was quantified
using a commercially available assay system (Luciferase Assay
System, Promega). For replicons that do not express a luciferase
reporter, the antiviral effect was determined using an NS3
protease assay described previously [16]. Curve fitting and EC50
values were derived using non-linear regression analysis (XLFit).
Curves were extrapolated from duplicate points, and all experi-
ments were individually performed at least twice.
Western blot analysis
Cells were washed with PBS followed by lysis with RIPA buffer
containing protease inhibitors (Complete Mini; Roche) and
phosphatase inhibitors (PhoStop; Roche). Samples were placed
on ice for 15 minutes then pelleted. Supernatants were snap
frozen, and stored in at 280uC. Supernatants were run on 10%
Tris-Bis NuPage gels (Invitrogen) in MOPS buffer (Invitrogen) at
200 V for 2 hours under reducing conditions. Gels were
transferred to nitrocellulose using the iBlot (Invitrogen) set at
7 minute transfer. Westerns were performed using the SnapID
system (Millipore) or the BenchPro system (Invitrogen). Mouse
anti-NS5B (clone 3B1) antibody (Axxora), mouse anti-NS5A
antibody (Apath), and mouse anti-NS3 antibody (Virostat) were
used as primary antibodies for detection of NS5B, NS5A, and
NS3, respectively. For Westerns using chemiluminescence analy-
sis, HRP anti-mouse secondary antibody was used (Cell Signaling)
and finished blots were incubated briefly with Immunostar
Western C reagent (Bio-Rad) then analyzed using a Chemidoc
(Bio-Rad). For Westerns using infrared readout, LiCor IR Dye
Goat-anti-mouse-800CW was used as a secondary antibody and
finished blots were analyzed using the Licor Odyssey (Licor;
Lincoln, NE). For detection of biotin, IR Dye 700-linked
streptavidin was used.
BacMam Cloning and Infection
The coding sequences of full-length and 21 C-terminal amino
acids truncated NS5B were amplified from the genotype 1b (Con-
1) replicon plasmid pFK_i341_PiLucNS3_39_ET by PCR. The 59
PCR primer contained a HindIII restriction site, trinucleotide
ACC and a methionine codon. The 39 PCR primer contained
coding sequence for a stop codon and an XbaI restriction site. In
cases in which a C- or N-terminal His tag were desired, an octahis
sequence was also included in the appropriate primer sequence.
The amplified fragment was then digested with HindIII and XbaI,
and cloned into an analogously digested pFastBacMam vector
[17]. Recombinant virus was generated by using the Bac-to-Bac
system (Life Technologies, Carlsbad, CA). Virus was further
amplified by propagation in Sf21 cells grown in suspension. Sf21
cells used for overexpression of HCV proteins were obtained from
Tegobuvir’s Novel Mechanism of Action
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5610
6 Lunet cells were plated in DMEM/10% FBS/NEAA in a
T225 flask and incubated overnight in a 37uC5 %C O 2 incubator.
For each flask of cells to be infected, 35 mls of BacMam virus
reagent was combined with 70 mL of DMEM/10% FBS/NEAA
media and concentrated down to 40 mL using a Vivacell 100
concentrator (Sartorius; MWCO 50,000). Media was removed
from Lunet cells and the 40 mls of concentrated BacMam virus
was added to each T225 flask. Three hours later, compound was
added to the desired concentration as well as sodium butyrate to a
final concentration of 10 mM. Flasks were incubated overnight in
a3 7 uC5 %C O 2 incubator. The next day, the BacMam virus/
media mixture from flasks was placed in a 250 mL disposable
centrifuge bottle. Cells were washed with PBS, trypsinized, and
added to the centrifuge bottle mixture. Cells were pelleted
10 minutes at 1200 rpm, washed with PBS, and pelleted again.
Pellets were flash frozen on dry ice and stored at 280uC until
purification.
Purification of NS5B for Mass Spectrometry Analysis
Cell pellets were resuspended and lysed in lysis buffer (50 mM
Tris pH 7.5, 350 mM sodium chloride, 2 mM PMSF, 5 mM
DTT plus Complete Mini protease inhibitor table). Following lysis,
debris was pelleted by centrifugation at 14,000 RPM for 5 minutes
at 4uC. Supernatant was incubated overnight with protein A
Dynabeads (Life Sciences, Carlsbad CA) previously conjugated to
anti-NS5B antibody (Axxora; Clone 12B7). The next day, beads
were washed three times with lysis buffer. Captured protein was
eluted in 100 mM Glycine (pH 2.4)/4 M Urea and immediate
analyzed by mass spectrometry.
Mass Spectrometry
Mass spectrometry of immunoprecipitated protein samples was
performed on an Agilent 6210 Time of Flight Mass Spectrometer
with an Agilent 1200 Rapid Resolution HPLC using Masshunter
B.02 Acquisition software. The samples were run on an Agilent
Zorbax 300 Extend C18 Rapid Resolution column at 70uC, using
reverse phase chromatography with a gradient from 20% to 90%
acetonitrile containing 0.1% formic acid. Data was processed via
Agilent Masshunter B.03 Qualitative Analysis, with Bioconfirm
upgrade, allowing for protein deconvolution.
Cytochrome P450 Overexpression
CYP1A1 DNA was purchased from Open Biosystems (CYP1A1
precision lentiORF) while CYP1A2 (accession NM_00761.3) and
CYP3A4 (accession DQ924960.1) DNA were synthesized by
Integrated DNA Technologies (IDT). CYP DNA were amplified
using 22.5 mL Accuprime pfx supermix (Invitrogen), in reactions
containing 0.25 uL of 20 uM forward primer, 0.25 uL of 20 uM
reverse primer and 10 ng of DNA. PCR reactions were cycled at
95uC for 5 minutes, then 35 cycles of 95uC for 15 seconds, 57uC
for 30 seconds followed by 68uC for 2 minutes. Primer used for
amplifications were CYP1A1 forward primer 59-CAC CGT ACA
AAA AAG CAG GCT-39; CYP1A1 reverse primer 59-TTA GTA
CAA GAA AGC TGG GTC-39; CYP1A2 forward primer 59-
CAC CAT GGC TCT GTC CCA GTC-39; CYP1A2 reverse
primer 59-TTA ATT TAT GCT GAA TCT CAA C-39;
CYP3A4 forward primer 59-CAC CAT GGC ACT GAT CCC
GGA-39; CYP3A4 reverse primer 59-TTA GGC GCC GCT
CAC GGT GCC-39. PCR reactions were separated on a 1%
agarose gel then purified using the QIAquick Gel Extraction Kit
(Qiagen) as per manufacturer’s instructions. The purified CYP
PCR products were ligated into lentivirus vector (pLenti6/V5-D-
TOPO) using pLenti6/v5 directional TOPO cloning kit (Invitro-
gen) as per manufacturer’s instructions and transformed into Stbl3
compentent cells. DNA was extracted from selected colonies and
were purified using QIAprep Spin Miniprep Kit (Qiagen) and
screened for correct insert size using PCR. Plasmids containing the
correct size of insert were confirmed by sequencing (ELIM
Biopharmaceuticals; Hayward, CA).
Transfection of SL3 cells
SL3 cells were plated onto 10 cm cell culture plates at a density
of 1.5610
6 cells, 24 hours prior to transfection. Each dish of cells
was transfected with 15 mg CYP1A1, CYP1A2 or CYP3A4
pLenti6/V5-D-TOPO DNA using 45 mL of TransIT-LT1 (Mirus
Bio) according to manufacturer’s instructions. Transfection
efficiency was determined using RT-PCR to detect expression
levels 48 hours post-transfection.
Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
Total RNA was isolated using an RNeasy kit and QIAshredder
(Qiagen) according to manufacturer’s instructions with DNase
digestion. Quantitative analysis of mRNA was carried out on a
7300 Real Time PCR machine (Applied Biosciences). The 25 mL
reaction mixture contained 1.25 mL of CYP primer (206)o r
0.25 mLo f1 0 mM Fam-labeled GAPDH forward primer and
0.25 mLo f1 0 mM unlabeled reverse primer, 12.5 mLo f
QuantiTect Multiplex RT-PCR Master Mix (Qiagen), 9.5 mLo f
nuclease-free water, 0.5 mL of RNA and 0.125 mL of RT-enzyme.
Human primers for CYP1A1 (Hs01054797_g1), CYP1A2
(Hs00167927_m1) and CYP3A4 (Hs00604506_m1) were pur-
chased from Applied Biosystems and GAPDH (100H-01) was
purchased from Invitrogen. The fold change in the level of
CYP1A1, CYP1A2 or CYP3A4 between normal or overexpressed
cells were normalized to the levels of GAPDH. The RT-PCR data
were analyzed using the relative gene expression method, DD-Ct.
Results
Treatment of HCV replicon containing cells with TGV
results in the formation of an NS5B ‘‘doublet’’
TGV (Scheme S1) is a potent in vitro inhibitor of the replication
of GT 1a and 1b subgenomic HCV replicons. We first examined
what effect TGV treatment of GT 1b replicon cells (1b-Rluc) has
on the formation of HCV non-structural proteins by performing
Western blot analysis of TGV-treated cultures. Interestingly,
treatment of the GT 1b replicon cells with TGV (50 nM; ,50 fold
over EC50) resulted in a secondary, faster-migrating NS5B
polymerase species by SDS-PAGE such that NS5B was visualized
as a doublet by Western blot (Fig. 1. Monitoring of NS5B doublet
formation at a fixed concentration of TGV over time revealed that
the amount of lower band formed correlated with the time of
exposure to TGV. This effect appeared to be specific to NS5B, as
no aberration in protein mobility was observed by SDS-PAGE for
either NS5A or NS3 proteins after TGV treatment of replicon cells
(Fig. 1A). Furthermore, NS5B doublet formation was not observed
when replicon-containing cells were treated with other classes of
inhibitors including NS5B NNIs (site II inhibitor VX-222, site III
inhibitor A-782759 and site IV inhibitor HCV-796), a nucleoside
chain terminator (29CMeA), or a protease inhibitor (BILN-2061),
suggesting that this effect is unique to TGV (Fig. 1B).
NS5B doublet formation correlates with TGV potency
We next explored whether TGV treatment (at 50 nM) also
resulted in the formation of a NS5B doublet in GT 1a containing
Tegobuvir’s Novel Mechanism of Action
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the formation of NS5B doublet was examined over time. Although
the NS5B doublet was observed in GT 1a replicon cells, the
appearance of the lower band was delayed in comparison to GT
1b replicon cells (Fig. 1C). TGV displays sub-genotypic variations
in potency such that the GT 1a EC50 is 17-fold higher than that
observed in GT 1b (Fig. 1D). We increased the concentration of
TGV used in the GT 1a replicon 10-fold to determine if increased
drug load could overcome the observed delay in doublet
formation. A 10-fold higher (500 nM) concentration of drug led
to appearance of the lower NS5B band in GT 1a replicon at an
exposure time similar to GT 1b, suggesting that doublet formation
correlates with TGV antiviral potency (Fig. 1C).
In addition to the sub-type differences in TGV potency, TGV is
vastly less potent against the GT 1b (Con-1) replicon in the the
HeLa cell line (EC50.10 mM). This was unexpected considering
the fact that the HeLa replicon was inhibited by all other
compounds tested at levels similar to those observed for the 1b-
Rluc replicon (data not shown). We wanted to determine if doublet
formation occurred in the HeLa replicon following treatment with
TGV. Even at the solubility-limited dose of 10 mM of TGV no
doublet formation was observed (Fig. 1C). This result further
supports the relationship of HCV replication inhibition to doublet
formation, as the concentration tested was below the HeLa
replicon EC50.
Finally, we examined doublet formation in Huh7 cells carrying
a replicon harboring a TGV-resistance mutation. NS5B Y448H is
the primary mutation conferring both in vitro and in vivo reduced
susceptibility to TGV. GT 1b Y448H NS5B replicons are 36-fold
less susceptible [2]. To this end, both wild-type and Y448H GT 1b
replicons were transiently transfected into Huh7 cells and cells
were analyzed by Western blot analysis for NS5B doublet
formation hours following a 24 hr treatment period with varying
concentrations of TGV (Fig. 1E). As anticipated, the NS5B lower
band was observed in extracts of cells that carry the wild-type
replicon and that had been incubated with TGV at a concentra-
tion as low as 10 nM. However, the lower band was only faintly
visible in extracts of cells that carried the Y448H replicon that had
been incubated with 100 nM of TGV. When lower concentrations
of TGV were used in the Y448H system no doublet was observed.
Taken together, these data indicate that the modified NS5B
species observed following treatment with TGV is correlative with
TGV activity.
NS5B doublet formation does not require other viral
proteins and is not the result of a cleavage event
As the nature of the modified NS5B double band likely held the
key to the TGV mechanism of action and the material produced
in replicon containing cells proved insufficient for further study, we
sought to replicate this phenomenon in a replicon free system. We
therefore utilized a BacMam overexpression system to express only
GT 1b NS5B polymerase in Huh7 cells. TGV-treated Huh7 cells
infected with a full-length NS5B-encoding BacMam virus were
examined by Western blot analysis to determine if a NS5B doublet
was detectable as observed in the replicon system. As with GT 1b
replicon cells, a NS5B doublet was observed in recombinant NS5B
expressed using the BacMam system. This demonstrates that other
viral proteins are not required to observe this behavior in the
presence of TGV (Fig. 2A).
A more soluble deletion construct of NS5B polymerase with the
membrane insertion domain removed (D21) was expressed using
the BacMam system and similarly exhibited doublet formation
following TGV treatment (Fig. 2B). Since the lower band of the
NS5B doublet migrates 1–2 kDa faster by SDS-PAGE, we
hypothesized that this could be due to a deletion at either of the
Figure 1. TGV treatment leads to formation of an NS5B double band detectable by Western analysis. A) NS5B, NS5A, and NS3 Western
blots of lysates from 1b (Con-1) replicon cells treated with 50 nM TGV for various periods of time. B) NS5B Western blot of lysates from 1b replicon
cells treated for 24 hours with known HCV inhibitors at 506EC50 concentrations. C) NS5B Westerns of cell lysates collected at various times from Huh-
luc 1a replicon cells treated with 50 nM or 500 nM TGV and lysates from HeLa 1b replicon cells treated with 10 mM TGV. D) TGV EC50 values in Huh-luc
1a, 1b, and HeLa 1b (clone SL3) replicon cell lines. E) Western blot of lysates from Lunet cells transiently transfected with wild-type or NS5B Y448H
mutant 1b Pi-Rluc replicons and treated with varying concentrations of TGV for 24 hours.
doi:10.1371/journal.pone.0039163.g001
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system, we separately engineered and expressed both N- and C-
terminal His-tagged NS5B D21. The tagged proteins were
expressed in the presence of TGV treatment and immunoprecip-
itated from cell lysates to determine the nature of the lower band
(Fig. 2C). We first performed an immunoprecipitation utilizing an
anti-NS5B antibody to pull-down His-tagged NS5B, followed by
SDS-PAGE and Western blot analysis using an anti-His antibody.
Analysis of the isolated NS5B species revealed that both the N-
and C-terminal His tags were intact for both the upper and lower
migrating species of the doublet. This indicates that the lower
band is not the result of a terminal cleavage. By means of
confirmation, the opposite experiment was performed in which the
proteins were immunoprecipitated using an anti-His antibody then
subjected to Western blotting using an anti-NS5B antibody.
Likewise, both NS5B doublet species were formed demonstrating
that the N- and C-termini of NS5B are intact in the lower band
species and thus that the observed lower band is not the result of
protein cleavage or degradation.
Mass spectrometry reveals an additional higher
molecular weight peak in NS5B from TGV-treated cell
culture
In lieu of efficient methods to separate the two NS5B species for
further characterization, we next employed sensitive biophysical
methods to further deduce the nature of the NS5B doublet from
the mixture. We immunoprecipitated NS5B from lysates derived
from DMSO or TGV-treated BacMam D21 NS5B overexpressing
cells using an anti-NS5B antibody. Isolated NS5B protein was
eluted from the IgG capture beads and immediately analyzed on
the mass spectrometer. Analysis of NS5B D21 preparation from
DMSO treated control samples resulted in a ,64 kDa peak as
anticipated (Fig. 3A). Though NS5B D21 isolated from TGV-
treated culture contained a similar peak at ,64 kDa, a second
major peak of higher molecular weight was also observed that was
unique to the TGV treated sample. Measurement of the molecular
weight difference between the two observed peaks resulted in an
observed mass change of 820.54 Da. To determine if the
additional peak was related to the NS5B D21 parent peak, we
repeated the experiment with analogs of TGV, compounds 1 and
2 (Scheme S1). In both cases, a second major peak was also
observed in the chromatogram, which resulted in mass differences
of 788.9 and 788.7 Da, respectively (Fig. 3B). The fact that
compounds of different molecular weights can lead to unique peak
locations within the deconvoluted spectra suggests that the second
observed peak results from binding of the compound to NS5B plus
an additional modification. Interestingly, when the molecular
weight of the test compounds was subtracted from the mass of the
respectively identified second peaks, TGV and compound 1
yielded a difference of 303 Da, while compound 2 resulted in a
difference of 286.8 Da. This suggested that the modification did
not simply result from the addition of another molecular moiety,
but rather a more complex phenomenon dependent on the
chemistry of the compound.
A TGV-related biotinylated compound can be detected in
the lower band of NS5B via Western Blot
Prompted by the highly suggestive results from the mass
spectrometry experiments, we collected more evidence to confirm
that the aberrant migration of TGV treated NS5B is due to
compound adducting to NS5B. To this end, BacMam NS5B over-
expressing cells were treated with a potent biotinylated TGV
analog, compound 3, and lysates of these cultures were subjected
to SDS-PAGE (Fig. 4A). Western blot analysis was then performed
using a FITC-conjugated secondary antibody for NS5B detection
and Texas Red-linked Streptavidin. As with TGV, a NS5B
doublet was observed upon treatment with the biotinylated analog.
In addition, the Texas Red signal indicating biotinylation was
detected in the faster migrating NS5B doublet species of lysates
from BacMam over-expressing cells treated with the biotinylated
TGV analog, but not in DMSO or non-biotinylated TGV control
lysates. We then performed a similar experiment using the 1b-Rluc
replicon in Huh-7 cells (Fig. 4B). As observed in the BacMam
system, the biotinylated signal was detected in the faster migrating
band of NS5B doublet from compound-treated replicon cells,
implying that the alternate NS5B species resulting from TGV
treatment appears to be due to covalent adduct formation between
compound and the NS5B protein.
Glutathione contributes to TGV activity
Though TGV has been shown to be metabolically very stable
(the elimination half-life of TGV in humans is 10–15 hours [18],
preclinical metabolite identification studies revealed small amounts
of GSH adducts with oxidized versions of TGV (data not shown).
In addition, selected cytochrome P450 (CYP) inhibitors were
previously shown to alter the antiviral potency of TGV. When
TGV was combined in antiviral assays with a CYP1A inhibitor,
but not a CYP 3A4 inhibitor, a dramatic decrease in antiviral
potency was observed [2]. Taking this into consideration as well as
the 820 Da mass difference from the mass spectrometry studies,
we surmised that NS5B-TGV adduct formation may result from
the oxidative metabolism by CYPs and incorporation of GSH into
the complex. To determine the contribution of GSH to TGV
activity, we pre-treated replicon cells with L-buthionine sulfox-
imine, a glutathione synthase inhibitor, to deplete GSH prior to
subjecting the GSH-depleted replicons to TGV EC50 analysis
(Fig. 5A). We observed a 171-fold change in the TGV EC50 in
BSO-treated replicon cells as compared to control-treated cells.
No significant changes in potency were observed utilizing the site
II NNI VX-222, suggesting that GSH specifically contributes to
TGV activity. As anticipated, NS5B over-expressing cells also
Figure 2. NS5B double band formation in TGV-treated NS5B
overexpressing cells. A) NS5B Western blot of lysates collected from
TGV-treated Lunet cells expressing full-length NS5B via a BacMam
system. Overexpressing cells were treated for 16 hours with various
concentrations of TGV and compared to lysates from replicon cells
treated for 24 hours with 50 nM TGV or DMSO as a control. B) Western
analysis of TGV-treated cells overexpressing a 21 amino acid C-
terminally truncated NS5B (D21). C) Immunoprecipitation and Western
blots of overexpressed D21 NS5B encoding an N- or C-terminal His tag.
NS5B Western blotting of anti-His immunoprecipitated material and His
Western blotting of anti-NS5B immunoprecipitated material are shown.
doi:10.1371/journal.pone.0039163.g002
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TGV when co-treated with BSO (Fig. 5B). Taken together, these
data suggest that GSH contributes to TGV antiviral activity.
CYP 1A1 activity is necessary for the antiviral activity of
TGV
Given the fact that (i) CYP 1A, but not CYP 3A4 inhibitors,
result in a decreased antiviral effect of TGV and (ii) the
imidazopyridine are the only class of HCV inhibitors with poor
anti-HCV activity in the HeLa replicon system (SL3), we
hypothesized that this dearth of antiviral effects may be due to
low levels of either CYP activity or reduced GSH levels in HeLa
cells. GSH levels in HeLa cells were found to be comparable to
those in hepatoma cells (data not shown). We then utilized q-
RTPCR to gauge the expression of CYPs 1A1, 1A2, and 3A4 in
HeLa SL3 versus 1b-Rluc replicon cells. SL3 cells displayed 7- to
16- fold lower expression of CYP mRNA as compared to the Huh-
7-based 1b-Rluc replicon (Fig. 6A). We next wanted to determine
if we could evoke TGV susceptibility in the SL3 replicon by
transiently overexpressing CYPs 1A1, 1A2, or 3A4. The SL3
replicon cells became 1200-fold more sensitive to TGV when
overexpressing CYP 1A1, but not 1A2 or 3A4, to reach EC50
values similar to those observed in the Huh7 replicon system
(Fig. 6B). Note that with the different expression levels of CYP 1A1
tied to TGV activity, it seems conceivable that genotypic
variations in antiviral activity can only be referred to the sequence
of the replicon if the same host cell line is used. No difference was
observed in any of the SL3 cell lines using control inhibitors HCV-
796 and 29CMeA showing that this effect is specific to TGV.
These data demonstrate that CYP 1A1 expression levels are
essential to TGV activity and suggest that CYP 1A1 metabolism is
necessary for TGV to exert an antiviral effect.
Discussion
TGV is a member of the imidazopyridine class of antivirals
which emerged from phenotypic screens [19,20]. The viral
polymerase was established as a molecular target on the basis of
reverse genetics. Besides the C316Y mutation near the polymerase
active site, several other individual mutations, all in the beta-loop
of the thumb domain lead to significant loss in sensitivity to TGV
(C445F, Y452H and Y448H) [2]. However, TGV does not inhibit
the activity of the HCV polymerase in biochemical assays nor did
we find evidence for direct NS5B binding via biophysical methods,
i.e. DSC and SPR (data not shown). This apparent discrepancy
was largely resolved in light of our recent evidence of the
involvement of metabolic activation [2]. In co-dosing experiments
with various cytochrome P450 inhibitors, replicon-harboring cells
became markedly less sensitive to TGV. Indeed, pan-P450 CYP
inhibitors resulted in shifts in the EC50 values of TGV. Several,
mostly CYP 1A specific inhibitors, proved sufficient to result in this
decreased activity. This suggests involvement of a specific
oxidative metabolism in the TGV mechanism of action. Such
results help explain the lack of conclusive results using more
conventional in vitro strategies to determine TGV’s MOA.
The serendipitous discovery of a NS5B doublet observable by
SDS-PAGE provided a marker to experimentally deduce the TGV
mechanism of action. From the array of HCV (RdRp) inhibitors
studied, only the imidazopyridines result in the formation of the
second, faster migrating NS5B band. Moreover, the time at which
Figure 3. Mass spectrometry identifies higher molecular weight peak in TGV-treated NS5B samples. A) Mass spectrometry analysis of
material immunoprecipitated by anti-NS5B antibody from D21 NS5B overexpressing cells treated with TGV or DMSO. B) Compound molecular
weights and mathematical analysis of resulting peaks detected by mass spectrometry of NS5B samples treated with TGV and analogs.
doi:10.1371/journal.pone.0039163.g003
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potency of the inhibitor. Furthermore, in cells that carry TGV
resistant replicons, substantially increased concentrations of drug
are needed to result in the formation of a detectable NS5B
doublet. Thus the NS5B doublet appears to be a phenotypic
hallmark of anti-HCV activity of the imidazopyridine class of
compounds.
Due to limitations in the amount of NS5B protein recoverable
from the replicon system (Fig. 1A) we utilized a BacMam-based
recombinant expression system to produce full-length NS5B as
well as the more soluble NS5B D21 in large quantities. The
signature NS5B doublet was indeed formed when NS5B was
produced in the absence of other HCV proteins and treated with
TGV. As our NS5B overexpression system could not be optimized
to allow analysis of the NS5B doublet bands individually we
characterized the NS5B species as a mixture. We quickly ruled out
that the 2 kDa faster moving band reflects a TGV-induced protein
truncation as both N- and C-termini were found intact by Western
blot analysis (Fig. 2C).
To gain further insight into the identity of the second NS5B
band, we performed high resolution mass spectrometry on the
immunoprecipitated protein fraction containing the NS5B dou-
blet. When analyzing the material obtained from TGV treatment,
one additional peak unique to the TGV-treated sample was
evident, exhibiting a mass that was 820 Da larger than that of
NS5B protein from DMSO-treated cells (Fig. 3A). As this
additional mass differs for each inhibitor used for incubation with
the overexpression system, it became evident that the inhibitors
must be part of the additional mass observed. It came as a surprise
that the covalent NS5B-TGV complex migrates faster in a
commercial SDS-PAGE system than unmodified NS5B although
it has a higher molecular weight. However, SDS-induced
denaturation which is generally thought of as a charge mediated
unfolding process, may lead to protein species of different
compactness, impacting their migration rates. In the NS5B-
TGV case, adding a branching point with an additional
hydrophobic moiety could lead to a more compact species.
Alternatively, the branched hydrophobic moiety may bind
disproportionally more SDS which could also yield a faster
migration rate.
An important clue for the understanding of the 820 Da
difference came from the preclinical metabolite identification
studies of TGV and other less metabolically stable analogs using
human and dog liver microsomes. One typically observed
metabolite of the imidazopyridine analogs showed the addition
of GSH along with addition of oxygen and loss of a fluoride ion
from the phenyl moiety, corresponding to a MW of 820 in the case
of TGV, identical to the NS5B mass shift. The latter shift is 4 Da
smaller than the combined molecular weight of TGV and GSH
(517+307=824) which can be explained by fluorine/oxygen
exchange (Scheme S2). Compounds 1 and 2 (Scheme S1) differ
only by the halogen atom on the phenyl moiety. The difference
between the sum of compound and GSH MW and the observed
mass shift corresponds to the molecular weight difference of the
corresponding halogen and oxygen (Fig. 3B; MW HF – MW
O=20–16=4 for TGV and compound 1; MW HCl – MW
O=36–16=20 for compound 2). This observation led to the
hypothesis that an oxidative metabolite of TGV together with
GSH covalently modifies the NS5B protein to render it inactive.
Figure 4. Western analysis of NS5B treated with biotinylated
TGV analog shows presence of compound in faster migrating
component of double band. A and B Top) Anti-NS5B Western blot of
lysates from DMSO-, TGV-, and biotin compound-treated A) D21 NS5B
overexpressing cells and B) 1b (Con-1) replicon cells. A and B Middle)
Fluorochrome-linked streptavidin detection of biotinylated compound
3. A and B Bottom) Merge of NS5B and biotin detection reveals signal
co-localization of faster migrating NS5B species and compound.
doi:10.1371/journal.pone.0039163.g004
Figure 5. Reduction of GSH by BSO alters TGV potency and
NS5B double band formation. A) EC50s of TGV and VX-222 in 1b
replicon cells co-treated with BSO. Replicon cells were pretreated for
24 hours with 5 mM BSO to reduce GSH prior to compound addition. B)
NS5B Western blot of lysates from full-length NS5B overexpressing
Lunet cells treated varying concentrations of BSO added together with
10 mM TGV.
doi:10.1371/journal.pone.0039163.g005
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the anti-HCV activity of TGV was previously obtained via
inhibitor studies [2]. Additional evidence was obtained when CYP
1A1 was overexpressed in the HeLa cells that carry replicons. In
HeLa cells TGV does not efficiently inhibit HCV replicon
replication. Overexpression of the CYP 1A1 isoform, but not
CYP 1A2 or CYP 3A4, restores susceptibility to TGV without
affecting the susceptibility to other unrelated NS5B inhibitors
(Fig. 6B). Furthermore, the dependence of TGV activity on GSH
was established by GSH depletion studies where replicon cells
were pretreated with BSO, an inhibitor of the penultimate step of
GSH synthesis (Fig. 5B).
Overall, it is clear that oxidative metabolic activation of TGV
and normal GSH levels are requirements for TGV to affect
antiviral activity. Though our data cannot definitively establish the
complete molecular mechanism of TGV, it allows for a plausible
explanation for the molecular mechanism of TGV activity as
depicted in Scheme S2. Similar to the metabolism of many fluoro-
aromatic compounds [21], TGV (Scheme S2, (1)) is likely oxidized
to an epoxide intermediate (2) which can equilibrate with
intermediate (3). The latter can eliminate the fluoride ion yielding
ketone (4). The imidazopyridine ring system adjacent to the 2-
fluoro-phenyl uniquely allows for a highly stabilized, conjugated
intermediate with a double bond between the rings. This creates
three different possibilities for a nucleophilic attack by GSH or
another reactive cysteine residue (labeled A, B and C on structure
(4)). In the case of GSH attacking positions A or B, the ensuing
adducts (5a) and (5b) would quickly tautomerize to aromatic,
phenol analogs (6a) and (6b). The latter analogs exhibit molecular
weights of 820 Da and correspond to the putative TGV
metabolites as discussed above. Pathway C, however, involves an
attack at the ipso-carbon of the oxidized phenyl subsituent. This
attack would lead to adduct (7) which cannot tautomerize to an
aromatic phenol structure but is instead prone to a second
nucleophilic attack yielding double adducts (8a) and (8b). The
possibility of such a double addition is supported by the
observation of minor oxidative metabolites of TGV analogs with
two GSH molecules added (data not shown). To explain the NS5B
doublet formation, we suggest that reactive intermediate (4)
undergoes pathway C, with a subsequent addition of GSH and
NS5B. The nucleophile of the latter could be the thiol group of an
exposed cysteine residue as has been described in earlier reports
[22,23,24]. In the case of proposed intermediate (4) from Scheme
S2, it is unclear which addition occurs first; initial GSH addition is
probable since GSH is much more abundant than NS5B in the
cell.
Although the proposed mechanism of action is plausible,
additional evidence for covalent addition of TGV in the replicon
system was desired. As several attempts to demonstrate incorpo-
ration of radiolabelled compound into the lower band of the NB5B
Figure 6. Overexpression of CYP1A1 in SL3 (HeLa GT 1b) replicon cells restores sensitivity to TGV. A) qPCR analysis of CYP1A1, 1A2, and
3A4 mRNA levels in 1b Rluc replicon, control SL3 HeLa 1b replicon cells, and SL3 HeLa 1b replicon CYP1A1-overexpressing cell lines. B) TGV, HCV-796,
and 29CMeA EC50s in SL3 control and CYP overexpressing cell lines.
doi:10.1371/journal.pone.0039163.g006
Tegobuvir’s Novel Mechanism of Action
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39163doublet failed, we employed a more sensitive method using the
biotinylated TGV analog compound 3 (Scheme S1). The presence
of biotin was detected via immunostaining with a streptavidin
antibody (Fig. 4) in both BacMam and replicon-derived NS5B
preparations. This demonstrates unambiguously that the biotiny-
lated analog is present in the lower band of the doublet obtained
from both NS5B preparations.
To summarize, TGV exerts its potent inhibition of HCV
replication via a unique and so far unexplored mechanism.
Following CYP-mediated oxidative metabolic activation of the
fluorophenyl moiety and assistance of GSH, TGV binds covalently
to NS5B, thereby disrupting viral replication. This molecular
mechanism is unexpected, considering that replicon containing
cell lines are typically metabolically compromised and only
minuscule amounts of TGV’s oxidized GSH-adducts are found
in systemic circulation (DMPK data to be published elsewhere).
This suggests that TGV’s active metabolites react with NS5B with
high specificity and efficiency as NS5B should only be present in
the liver (the target organ of HCV replication), where GSH levels
are high compare to other tissues. When given with pegylated
interferon-alfa+RBV or in combination with other direct-acting
antivirals, TGV’s covalent MOA has not been an impediment for
TGV to be generally safe, well-tolerated and associated with
potent antiviral activity [25].
Supporting Information
Scheme S1 Compounds used in this study.
(TIF)
Scheme S2 Proposed chemical mechanism of TGV
activiation via CYP mediated oxidative metabolism
and involvement of GSH. Refer to main text for explanation
of pathways A–C and molecular species 1–8.
(TIF)
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